Safety and Efficacy of Fecal Microbiota Transplantation
Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- Not applicable (NA in the registry)
- Sponsor
- Chinese University of Hong Kong
- Participants (registry)
- 450
- Start
- July 2019
- Primary completion
- October 2030 (planned)
- Study completion
- October 2030 (planned)
- Last registry update
- August 2024
- Countries
- Hong Kong
Conditions studied: Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome, Functional Dysphonia, Constipation, Clostridium Difficile Infection, Diabetes Mellitus, Obesity, Multidrug -Resistant Infection, Hepatic Encephalopathy, Multiple Sclerosis, Pseudo-Obstruction, Carbapenem-Resistant Enterobacteriaceae Infection, Vancomycin Resistant Enterococci Infection, Multiple Organ Dysfunction Syndrome, Dysbiotic Bowel Syndrome, MRSA Enteritis, Pseudomembranous Enterocolitis, Alopecia, Autism, Graft-versus-host Disease, Idiopathic Thrombocytopenic Purpura, Atopy or Allergy, Liver Disease, Alcohol Dependence, Psoriatic Arthropathy
Interventions: Fecal Microbiota Transplantation
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.